Stockscreener 앱 받기
0.882
4.22%
-0.0389
시간 외 거래:
.88
-0.002
-0.23%
전일 마감가:
$0.9209
열려 있는:
$0.92
하루 거래량:
241.86K
Relative Volume:
0.51
시가총액:
$128.30M
수익:
$49.09M
순이익/손실:
$-52.15M
주가수익비율:
-1.3569
EPS:
-0.65
순현금흐름:
$-45.93M
1주 성능:
-10.46%
1개월 성능:
-17.57%
6개월 성능:
-50.45%
1년 성능:
-39.59%
1일 변동 폭
$0.875
$0.9686
1주일 범위
$0.875
$1.02
52주 변동 폭
$0.8568
$2.04
바이오데식스 Stock (BDSX) Company Profile
명칭
Biodesix Inc
전화
303-417-0500
주소
919 WEST DILLON ROAD, LOUISVILLE
BDSX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
0.882 | 128.30M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
바이오데식스 Stock (BDSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-26 | 개시 | Craig Hallum | Buy |
| 2024-05-13 | 개시 | TD Cowen | Buy |
| 2024-05-03 | 개시 | Lake Street | Buy |
| 2021-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 개시 | BTIG Research | Buy |
| 2020-11-23 | 개시 | Canaccord Genuity | Buy |
| 2020-11-23 | 개시 | Morgan Stanley | Overweight |
| 2020-11-23 | 개시 | William Blair | Outperform |
모두보기
바이오데식스 주식(BDSX)의 최신 뉴스
Biodesix, Inc. to Release Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 - Nasdaq
Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 - GlobeNewswire
Insider Selling: Biodesix, Inc. (NASDAQ:BDSX) CEO Sells 83,660 Shares of Stock - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Insider Gary Anthony Pestano Sells 16,748 Shares - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) CFO Robin Harper Cowie Sells 24,664 Shares - MarketBeat
Stephens Inc. AR Makes New $303,000 Investment in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Biodesix CFO sells $22,794 in stock - MSN
Biodesix CEO Scott Hutton sells shares worth $77,318 - MSN
Biodesix chief commercial officer sells shares worth $16,198 - MSN
Biodesix Inc Stock: Insider Sales Spark Market Concerns - sharewise
Biodesix chief accounting officer Chris Vazquez sells $3,354 in stock - MSN
Biodesix chief accounting officer Chris Vazquez sells $3,354 in stock By Investing.com - Investing.com Australia
Biodesix CEO Scott Hutton sells shares worth $77,318 By Investing.com - Investing.com Australia
Biodesix chief commercial officer sells shares worth $16,198 By Investing.com - Investing.com Australia
Biodesix CFO sells $22,794 in stock By Investing.com - Investing.com Australia
BIODESIX Executives Sell Shares to Cover Taxes - TradingView
Biodesix Inc [BDSX] Shares Rise 5.00 % on Wednesday - Knox Daily
Market Watch: Biodesix Inc (BDSX)’s Noteworthy Gain, Closing at 1.05 - The Dwinnex
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Declines By 7.4% - MarketBeat
Reviewing Biodesix (NASDAQ:BDSX) and Sera Prognostics (NASDAQ:SERA) - Defense World
Barclays PLC Acquires 21,179 Shares of Biodesix, Inc. (NASDAQ:BDSX) - Defense World
BDSX stock touches 52-week low at $1 amid market challenges - MSN
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Drops By 7.4% - MarketBeat
The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27% - Simply Wall St
BDSX stock touches 52-week low at $1.11 amid market challenges - Investing.com
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test - MSN
Biodesix, Inc. (NASDAQ:BDSX) Shares Bought by Barclays PLC - Defense World
Preliminary results show sales boost for Biodesix - BizWest
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited) - GlobeNewswire
Biodesix Achieves Record 45% Revenue Growth to $71.3M as Lung Diagnostics Surges in 2024 - StockTitan
Geode Capital Management LLC Has $1.43 Million Stock Position in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study - The Manila Times
Biodesix's Lung Cancer Blood Test Outperforms PET Scans in Major Clinical Study - StockTitan
Biodesix, Inc. (NASDAQ:BDSX) Q3 2024 Earnings Call Transcript - MSN
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Expands By 44.7% - MarketBeat
Contrasting Biodesix (NASDAQ:BDSX) & MDxHealth (NASDAQ:MDXH) - Defense World
Wilmington Savings Fund Society FSB Takes Position in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
바이오데식스 (BDSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
3.50%
자본화:
|
볼륨(24시간):